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ABSTRACT 
Introduction: Infection with the human immunodeficiency virus (HIV) can result in severe 
immune suppression, often allowing infections that would normally be controlled by the immune 
system to persist in HIV-positive individuals. Many of these infections can in turn affect the 
dynamics of HIV disease progression. Specifically, we hypothesize that herpesvirus infections are 
associated with more rapid progression of HIV-1 disease, and chronic immune activation that can 
lead to the development of HIV/AIDS-associated cancers. Alternatively, we postulate that GB 
Virus C coinfection has been shown to have a protective effect against HIV-1 disease progression, 
and may reduce chronic immune activation in HIV-1 positive individuals.  
Methods: This study investigated the associations of cytomegalovirus, Epstein-Barr virus, human 
herpesvirus 6, human herpesvirus 8, and GB Virus C viral coinfections on the development of non-
Hodgkin’s lymphoma in MACS HIV-1 seroconverters pre-combination antiretroviral therapy 
(cART). 536 seroconverters pre-cART were included in the investigation, including 22 who 
developed non-Hodgkin’s lymphoma.  
Results: HIV-1 seroconverters who developed non-Hodgkin’s lymphoma pre-cART experienced 
CMV and EBV viremia significantly more frequently than those who did not develop non-
Hodgkin’s lymphoma. HIV-1 seroconverters who did not develop non-Hodgkin’s lymphoma pre-
cART were more frequently viremic for GBV-C. Levels of EBV viremia were significantly higher 
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in HIV-1 seroconverters who developed non-Hodgkin’s lymphoma, and levels of GBV-C viremia 
were significantly higher in the HIV-1 seroconverters who did not develop non-Hodgkin’s 
lymphoma. Additionally, HIV-1 seroconverters who had experienced EBV viremia progressed 
from HIV-1 seroconversion to lymphoma diagnosis more rapidly than those from whom EBV 
viremia was never detected. Conversely, those who experienced GBV-C viremia, but never 
experienced EBV viremia progressed more slowly from HIV-1 seroconversion to non-Hodgkin’s 
lymphoma. 
Discussion: This investigation supports the hypothesis that EBV and CMV coinfections drive 
HIV-1 disease progression and the development of HIV-associated non-Hodgkin’s lymphoma. 
The results also suggest that GBV-C plays a protective role against the development of non-
Hodgkin’s lymphoma in HIV-1 positive individuals. These findings are of public health 
significance, because knowledge gained regarding the risks associated with non-Hodgkin’s 
lymphoma development can contribute to the prevention and early detection of non-Hodgkin’s 
lymphoma.  
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1.0  INTRODUCTION 
Viral coinfections have important implications for human immunodeficiency virus type 1 (HIV-
1) disease progression. For example, human herpesvirus coinfections are associated with chronic 
immune activation and inflammation in individuals with HIV-1 (1). Chronic immune activation 
and inflammation not only contribute to HIV-1 disease progression, but also are liked to the 
development of negative health outcomes associated with HIV/AIDS such as cardiovascular 
disease and cancer. Previous Multicenter AIDS Cohort Study (MACS) investigations have 
documented associations between elevated levels of cytokines and chemokines as biomarkers of 
non-Hodgkin’s B-cell lymphoma in MACS HIV-1 seropositives (2, 3). Similarly, herpesvirus 
coinfections have been associated with the development of various types of non-Hodgkin’s 
lymphomas (NHL) in HIV-1 positive individuals; although, other studies have shown no 
significant association between herpesvirus infection and NHL (4, 5). 
GB Virus C (GBV-C) coinfection results in slower HIV-1 disease progression, and better 
health outcomes in HIV-1 positive individuals (6).  Recently, GBV-C has been associated with 
reduced monocyte and natural killer cell activation, and a trend toward reduced B-cell activation 
in HIV-1 positive individuals (7). Chronic B-cell activation is associated with the development of 
HIV-associated non-Hodgkin’s lymphomas (8). 
Thus, while herpesvirus coinfections drive HIV-1 disease progression and chronic immune 
activation in HIV-1 positive individuals, GBV-C has a protective effect on HIV-1 disease 
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progression, and is associated with reduced immune activation in HIV-1 positive individuals (1, 
9). Therefore, it is possible that GBV-C also has a protective effect against the development of 
HIV-1-associated NHL in HIV-1 positive individuals.  
Specific Objective: The specific aim of this investigation is to examine the role of 
activated human herpesvirus and GBV-C coinfections defined by the presence of nucleic acid 
viremia in the development of NHL in HIV-1 seroconverters in the MACS. It is hypothesized that 
in HIV-1 seroconverters, the risk of NHL development is enhanced by herpesvirus coinfections 
and reduced by GBV-C coinfection. 
1.1 HUMAN IMMUNODEFICIENY VIRUS  
HIV is a single stranded RNA lentivirus that is responsible for causing acquired immunodeficiency 
syndrome (AIDS) (10). AIDS is characterized by the deterioration of one’s immune system leading 
to life-threatening opportunistic infections, or cancers.   
1.1.1 Epidemiology and Transmission of HIV  
Since the Centers for Disease Control and Prevention (CDC) first reported the occurrence of severe 
immunodeficiency in five California men in 1981, it is estimated that over 75 million people have 
become infected with HIV and 36 million have died due to their infection (11). According to the 
World Health Organization (WHO), an estimated 35.3 million people were living with HIV in 
2012 (11). Although the prevalence of HIV varies greatly from country to country, the burden of 
HIV is greatest in sub-Saharan Africa where an estimated 70% of all infections occur (11). The 
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majority of HIV infections are due to the HIV-1 subtype of the virus, while the less common HIV-
2 strain is not widely seen outside of Africa (12). 
 
 
Figure 1. Global adult HIV prevalence 
Source: The World Health Organization, http://www.who.int/gho/hiv/hiv_013.jpg?ua=1 
 
 
In the United States, an estimated 1.1 million individuals are currently living with HIV, 
and an estimated 50,000 new infections occur each year (13). The epidemiology of HIV infection 
in the U.S. has changed greatly since the onset of the epidemic in the early 1980s. In the 1980s 
HIV predominately affected white men who have sex with men (MSM) living in U.S. cities. By 
2006, an estimated 46% of all people living with HIV in the U.S. were African American although 
African Americans constitute only 12% of the U.S. population (14). Although men still account 
for three-quarters of all persons living with HIV in the U.S., the percentage of new HIV infections 
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in women has increased steadily since the mid-1980s (13). High-risk heterosexual contact is now 
the second most common transmission route in the U.S. following male-to-male sexual contact 
(14). Additionally, the age of people living with HIV has continued to increase in the United States 
due to the introduction of combination antiretroviral therapy (cART). 24% of all people currently 
living with HIV are now over the age of 50, compared to only 17% in 2001 (14).  
HIV is transmitted through the sharing of bodily fluids including blood, semen, anal and 
vaginal fluids, and breast milk (15). Transmission routes of infection are unprotected sex, sharing 
of contaminated needles, blood transfusions or transplants, and mother-to-child transmission 
during pregnancy, birth, or breastfeeding (15). Certain high-risk sexual practices, and infection 
with other sexually transmitted infections (STIs) can place an individual at higher risk of 
contracting HIV infection (14). 
1.1.2 HIV-1 Replication Cycle 
HIV predominately infects CD4 T cells, but is also capable of infecting dendritic cells and 
macrophages (10). HIV-1 enters cells through interactions of gp120 envelope glycoproteins with 
CD4 molecules, and CCR5 or CXCR4 co-receptors on the cell surface (12). The glycoprotein gp41 
on the viral envelope then facilitates fusion with the plasma membrane so that the viral capsid may 
enter the cell. Upon entry, the viral reverse transcriptase transcribes the viral RNA into a 
complementary DNA copy that is integrated into the host genome by the viral integrase (12). The 
HIV-1 RNA genome may then be transcribed in activated T cells, or the infection can remain 
latent, which particularly occurs in memory T cells or dormant macrophages (12). First, transcripts 
of viral RNA are translocated from the nucleus and extensively spliced for the production of Tat 
and Rev proteins (12). When levels of these proteins increase, viral transcripts are left unspliced 
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or singly spliced in order to produce all necessary structural components of the mature virion (10). 
These structural components assemble along with unspliced viral RNA in order to produce mature 
HIV-1 virus particles that bud from the cell (12). 
1.1.3 HIV-1 Pathogenesis and AIDS 
Acute HIV infection occurs at two-six weeks post infection, and is characterized by the onset of 
flu-like symptoms, and HIV viremia (16). During this time CD8 T cells are activated to kill HIV-
1 infected cells, CD4 T cell count decreases due to large quantities of cell death within the gut-
associated lymphoid tissue, and antibody production marks seroconversion (10). HIV infection 
then disseminates and establishes infection in lymphoid tissues throughout the body. Following 
the acute phase of HIV-1 infection, the level of virus that is maintained in blood plasma, known 
as the viral set point, has been shown to be indicative of future HIV disease progression (12). The 
asymptomatic latent phase of HIV infection can last between six months and twenty years, but on 
average lasts about ten years (12). Although infection is asymptomatic during this time, HIV-1 
infection persists and numbers of CD4 T cells decline. The persistence of HIV-1 infection during 
this time has been associated with the upregulation of markers of CD4 and CD8 T cell activation 
(17). Moreover, chronic immune activation is associated with the persistence of HIV infection and 
helps drive CD4 T cell depletion (18, 19). Once CD4 T cells decline, typically from normal levels 
of 800-1200 to levels of ≤500 cells per milliliter of blood, the symptomatic phase begins and 
opportunistic infections or cancer begin to occur (12).  Once CD4 T cells reach levels of 200 cells 
per milliliter an individual is typically clinically diagnosed with AIDS (12). Several negative 
health outcomes are associated with HIV progression and the onset of AIDS. Common 
opportunistic infections associated with AIDS include viral diseases due to herpesvirus infections 
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that will be described later in this study, and bacterial diseases such as tuberculosis or pneumonia. 
Additionally, HIV and AIDS-associated malignancies and neurodegeneration can develop. 
 
1.1.3.1 HIV-Associated Non-Hodgkin’s Lymphoma 
Approximately 90% of all lymphomas, the malignancies of the lymph system, are 
classified as NHLs (20). NHLs can occur in lymph nodes, the digestive tract, central nervous 
system, or proximal to the tonsils, and they are classified either as indolent or aggressive (21).  The 
majority of NHLs (85%) are of B cell origin, but a small percentage are of T cell origin (20). 
Unlike Hodgkin’s lymphoma, which originates only in abnormal Reed-Sternberg cells and 
commonly occurs in young adults, NHL exhibits over 30 unique subtypes and typically occurs in 
those over the age of 65 (22). Risk factors for NHL include age, male gender, Caucasian race, 
certain infections (e.g. EBV), chronic B cell stimulation, and immune deficiency disorders (20, 
23). 
NHL is the second most common malignancy seen in HIV-1-positive individuals, and is 
considered an AIDS-defining illness (21). Research suggests that between 5-20% of all HIV-
positive individuals will develop NHL compared to less than 1% of the general population (24, 
25). NHL in HIV-1-positive individuals is typically intermediate or high-grade, meaning that it 
will progress rapidly if left untreated (20). HIV-1-related lymphomas are categorized into three 
main groups; systemic NHLs, primacy central nervous system lymphomas, and primary effusion 
lymphomas (26).  
Systemic NHLs are the most common type of HIV-associated NHL and they include 
diffuse large B cell lymphomas and Burkitt lymphomas (26). While diffuse large B cell 
lymphomas typically occur late in HIV disease progression when CD4 T cell counts are low (<50 
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per ml), Burkitt lymphoma may develop among sustained levels of CD4 T cells (26). Chronic 
active B cell receptor signaling has been implicated as a pathogenic mechanism of development 
in diffuse, large B cell lymphomas, and Burkitt lymphoma has been shown to be associated with 
both EBV and HIV-1 infection (27, 28). The introduction of cART has reduced the incidence of 
NHL in those with HIV-1, and has helped improve the prognosis in those who develop NHL. 
However, unlike other subtypes of HIV-1-associated NHL, Burkitt’s lymphoma prognosis does 
not improve following the use of cART, for which the mechanism is not yet understood (29). 
Primary central nervous system lymphomas are B cell lymphomas that most frequently 
occur in the brain, but may also develop on the spinal cord (30). EBV is identified in nearly all 
primary central nervous system B cell tumors (20, 30). Previous to the introduction of cART the 
prognosis for HIV-positive individuals with primary central nervous system lymphomas was poor. 
This particular subtype is usually treated with radiation and chemotherapy, and the use of cART 
has increased mean survival time to 55 months (31).  
Primary effusion lymphoma (PEL) is a rare HIV-1 or AIDS-associated NHL that was 
previously known as body-cavity lymphoma. PEL is of B cell origin, and accounts for an estimated 
4% of all HIV-related NHLs, and they typically occur in the pleural space or abdomen (24). Human 
herpesvirus 8 (HHV-8; aka Kaposi’s sarcoma associated herpesvirus) is associated with the 
development of PEL, and most individuals who develop PEL already have either Kaposi’s sarcoma 
or multicentric Castleman’s Disease (24). The mechanism of oncogenesis promoted by HHV-8 in 
the development of PEL is not yet understood. In addition to HHV-8 infection, associations 
between EBV and PEL development have been suggested (24). cART initiation and combination 
chemotherapy are the recommended treatment for PELs; however, the prognosis remains poor 
with a mean survival time of five-seven months (24). 
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1.2 HUMAN HERPESVIRUSES 
Herpesviruses, of the Herpesviridae family, are widespread in nature with over 130 viruses 
utilizing a variety of host species as reservoirs. Highly prevalent in both the U.S. and global 
populations, there are eight types of herpesviruses that infect humans: herpes simplex virus 1 
(HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), 
cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7), and 
(HHV-8) (10).  Estimates suggest that 60-95% of the global population has been infected with at 
least one HSV, and in the U.S. 89% of children test positive for the EBV antibody by age 18 (32, 
33).   
 Herpesviruses are composed of a linear, double-stranded DNA genome encased in an 
icosahedral capsid (10). During symptomatic infection, viral DNA synthesis and capsid assembly 
occur in the nucleus of the host cell, which usually results in the destruction of the host cell (10). 
Following primary infection, herpesviruses are capable of remaining latent in host cells 
indefinitely while expressing only a small number of viral genes. Reactivation, and subsequent 
symptomatic infection can occur due to a variety of factors, particularly, immune suppression. 
Because of the high prevalence of herpesviruses, and the shared transmission routes of many 
herpesviruses and HIV-1, human herpesviruses are common coinfections with HIV-1 (34). 
Immune suppression and CD4 T cell depletion due to HIV-1 infection allows for the reactivation 
of persistent herpesvirus infections that contribute to the chronic immune activation and 
inflammation that drive the progression of HIV-1 disease and result in other negative health 
outcomes such as cardiovascular disease, cancer, and neurodegeneration (34). 
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1.2.1 Cytomegalovirus 
CMV is a betaherpesvirus that is capable of infecting a wide variety of tissues and cell types within 
a host, and causing systemic infection (10). Viral entry occurs following the adherence and fusion 
of the virion envelope protein and cellular membrane, and then capsid proteins deliver the viral 
genome to the nucleus for replication (35). CMV replication typically occurs in epithelial cells, 
endothelial cells, fibroblasts, or smooth muscle cells (36). The prevalence of CMV in the United 
States is estimated to be over 58% in people over the age of six (37). The infection is more 
prevalent in minority groups, particularly Hispanic Americans (81.7% prevalence) versus the 
prevalence in non-Hispanic white Americans (51.2%) (37). CMV is transmitted sexually, 
perinatally, by close contact, or through contaminated blood transfusions or organ transplants. The 
virus is shed in bodily fluids including urine, saliva, tears, breast milk, vaginal secretions, and 
semen (38). CMV is typically asymptomatic in immune-competent hosts, but may cause 
mononucleosis-like symptoms such as fatigue, fever, and enlarged lymph nodes in healthy 
individuals (38). In immune-competent individuals, CMV infection is usually self-limiting and 
does not require treatment. Like all herpesviruses, CMV infection persists in a host and can 
reactivate later in life causing illness if one becomes immune suppressed. This infection can be 
very serious in immune-compromised individuals such as transplant recipients, infants, and HIV-
1-positive individuals. 
1.2.1.1 CMV Infection in HIV-1 Positive Individuals 
 CMV is one of the leading opportunistic infections affecting those living with HIV/AIDS. 
CMV disease commonly manifests as retinitis, colitis, esophagitis, or meningoencephalitis (16). 
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T-cell immunity is a key host defense to CMV infections, and for this reason disease normally   
occurs in severely immune compromised individuals with CD4 T cell counts below 100 per ml (16).  
CMV is considered a cofactor in HIV-1 disease progression. Upon cell entry of the virus, 
interferon-stimulated genes are upregulated, with increased levels of interferon-β and other 
inflammatory cytokines (35). The immune activation resulting from persistent CMV infection can 
result in further T cell depletion, and diseases associated with chronic inflammation. Specifically, 
increased CMV-specific T cells have been associated with atherosclerosis, and CMV-infected 
tumor cells are associated with increased malignancy and chemoresistance (35, 39). In immune-
compromised individuals, CMV disease is usually treated with ganiciclovir or valganciclovir 
antiviral medications depending on clinical presentation of the infection (16).  
1.2.2 Epstein-Barr Virus 
EBV is a gammaherpesvirus that primarily infects B-cells and epithelial cells, but may infect T 
cells, NK-cells, and smooth muscle cell (35). Separate methods of entry are required for different 
cell types. In order to enter B cells, EBV proteins interact with the CD21 protein, and in order to 
enter epithelial cells EBV proteins interact with β integrins prior to viral fusion with the cell 
membrane (40). EBV is transmitted through saliva, blood transfusions, and organ transplants (16). 
As previously mentioned, EBV is highly prevalent in the U.S. with 89% of children infected by 
age 18 (32). Infection rates are higher in minority groups. (41).  
Primary infection typically occurs in children and is asymptomatic (90%). However, if 
primary infection occurs at an older age, infectious mononucleosis becomes more likely. 
Mononucleosis is characterized by elevated lymphocyte counts in the blood consisting of “atypical 
mononuclear” cells in the blood, usually CD8 T cells (10). Symptoms of infectious mononucleosis 
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set in approximately five-seven weeks post-infection and include fever, pharyngitis, 
lymphadenopathy, headache, abdominal pain, and nausea (16, 40). Symptoms typically last for 
three weeks, are self-limiting, and are treated with supportive care. In addition to a few serious 
complications that may occur due to infection, EBV has been implicated in numerous 
lymphoproliferative disorders that are most often seen in immune-compromised individuals (42, 
43). 
1.2.2.1 EBV Infection in HIV-1 Positive Individuals 
 HIV-1 positive individuals are at an increased risk of developing EBV-associated 
malignancies (43).  Reactivation of EBV infection is not necessary for the development of these 
proliferative disorders; instead, the viral genes expressed during latent EBV infection of 
lymphocytes are sufficient for the development of various lymphomas (43). Burkitt lymphoma 
can develop in individuals regardless of HIV-1 status. However, EBV DNA is detected in 
30-40% of HIV-associated Burkitt lymphoma cases (43). Additionally, EBV is implicated in 
over 95% of primary central nervous system lymphomas in HIV-1-positive individuals (42). 
Similar to HHV-8, EBV DNA is also associated with PEL (35). EBV is most commonly 
associated with B-cell lymphomas, but can also play a role in the development of other 
proliferative disorders such as T cell lymphomas and nasopharyngeal carcinoma (40). 
Treatment of EBV-associated malignancies in individuals with HIV/AIDS depends on the 
classification, and advancement of the disease. The utilization of cART resulted in a 
dramatic decrease in the prevalence of AIDS-associated malignancies in the 1990’s (40). 
However, as HIV-1 positive individuals continue to live longer, it is likely that the burden of 
EBV and HIV-associated lymphomas will rise.  
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1.2.3 Human herpesvirus 6 
HHV-6 is the collective name of the betaherpesviruses HHV-6A and HHV-6B. HHV-6 utilizes 
the CD46 receptor, and enters cells through fusion of the viral envelope protein and the cellular 
membrane (44). The wide array of cells that HHV-6 is capable of infecting includes B cells, T 
cells, DCs, NK Cells, and γ/δ T Lymphocytes (44). The virus often replicates in the salivary glands 
following infection, and is shed through saliva. This is believed to be the most common route of 
HHV-6 transmission, however, evidence suggests that it may also be transmitted vertically and 
sexually (45). Like most herpesviruses, HHV-6 is highly prevalent both globally, and in the U.S. 
with an estimated 95% of all people over the age of two being seropositive for HHV-6.  Primary 
HHV-6 infection commonly results in roseola infantum, a combination of high fever and rash that 
is not typically severe in the immune-competent children in which this disease most frequently 
occurs (45).  
1.2.3.1 HHV-6 Infection in HIV Positive Individuals 
Reactivation of HHV-6 infection can be dangerous in people living with HIV/AIDS, and 
can result in HHV-6 viremia, lymphadenitis, pneumonitis, retinitis, meningoencephalitis, and 
disseminated infection of organs (45). The frequency of HHV-6 reactivation in HIV-1 positive 
individuals has been reduced since the introduction of cART. HHV-6 infection contributes to HIV-
1 disease progression through the upregulation of cytokines, transactivation, and interference with 
dendritic cells’ ability to capture antigen (45, 46). Although HHV-6 accelerates HIV-1 disease 
progression, HHV-6 detection in peripheral blood mononuclear cells decreases during AIDS likely 
due to reduced levels of CD4 and CD8 T cells. The possible association between HHV-6 infection 
and AIDS-associated malignancies is not currently well understood. Recently, HHV-6 DNA was 
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detected in 86% nodular sclerosis Hodgkin’s Lymphoma (NSHL) cases, a finding that has been 
demonstrated in previous studies (47, 48). While investigations have found increased HHV-6 viral 
load in individuals with various types of lymphoma and leukemia, the mechanism or reason for 
increased HHV-6 load has not been defined, and may be due to increased dysregulation and 
dysfunction of the immune system due to HIV-1 disease progression and AIDS.  
1.2.4 Human herpesvirus 8 
HHV-8 is a gammaherpesvirus that has been associated with the development of several 
proliferative disorders most notably, Kaposi’s sarcoma (KS) (10). HHV-8 primarily infects B cells, 
but may also infect endothelial cells, prostate epithelial cells, nerve cells, and macrophages (35). 
Spindle cells are the primary target of HHV-8 in KS tumors (49). HHV-8 may be transmitted 
through infected sexually, vertically, through organ transplantation, and contaminated saliva (16). 
Prevalence of HHV-8 infection varies greatly by geography and among groups at various risks for 
contracting the virus. The overall prevalence of HHV-8 in the U.S. is estimated between 1-6%, but 
may be as high as 9.4% in heterosexual males, and 22% in MSM (35, 50). The prevalence is also 
much higher in some Mediterranean locations (Sicily 23.1%), and in Africa where the prevalence 
is estimated to be greater than 50% (10, 51). In those experiencing primary infection, HHV-8 rarely 
causes symptoms, but may result in a rash and fever. However, HHV-8 is associated with 
proliferative disorders including KS, PEL, and multicentric Castleman’s disease (35). 
1.2.4.1 HHV-8 Infection in HIV-1 Positive Individuals 
HIV-1 positive MSMs are a high-risk group for HHV-8 infection, for example 60% of 
MACS seroconverters have been viremic for HHV-8 at least once. Like all herpesviruses, latent 
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HHV-8 infection may be reactivated and cause disease in immune-compromised individuals. The 
reactivation and lytic replication of HHV-8 is critical to the development of HHV-8 -associated 
proliferative disorders (10). KS is a vascular tumor of proliferating spindle cells that typically 
affects the face, mouth, upper body, or even the respiratory and gastrointestinal tract (52) . There 
are four types of KS: classic KS that occurs typically in Mediterranean men, African endemic KS, 
immunosuppression-associated KS, and AIDS-associated KS (10). Inflammatory cytokines and 
vasoproliferative cellular cytokines induce lytic replication of HHV-8, and vasoproliferative 
cytokines and the HIV Tat protein contribute to tumor maintenance and KS pathogenesis (35). 
Antivirals aimed at reducing herpesvirus replication such as ganiciclovir have been shown to 
reduce the occurrence of KS, and cART can result in remission of KS in individuals with 
HIV/AIDS (52).  
 PEL is a rare, non-Hodgkin’s B cell lymphoma that typically occurs in visceral cavities 
(24). PEL is treated with a combination of chemotherapy and cART, which can result in regression 
of the disease (24). Unfortunately, the prognosis remains poor for PEL with a mean survival from 
diagnosis of 5-7 months (10). MCD is a systemic lymphoproliferative disorder that is characterized 
by expanded germinal centers, and hyperproliferation of B cells (10). Dysregulation and 
hypersecretion of IL-6, which promotes B cell growth and inhibits B cell apoptosis, is a common 
cause of MCD (35). In HHV-8-associated MCDs (approximately 50% of all MCDs) HHV-8 viral-
encoded cytokine, vIL-6, is hypersecreted (53).  
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1.3 GB VIRUS C 
GVB-C of the Flaviviridae family is a positive-polarity single stranded RNA virus (9). GBV-C, 
also previously known as the hepatitis G virus (HGV), is phylogenetically related to hepatitis C 
virus (HCV); however, unlike hepatitis viruses, GBV-C is lymphotrophic and non-pathogenic (9). 
A relatively common infection, estimates suggest that 1-2% of healthy blood donors in the United 
States are viremic for GBV-C, but the estimated prevalence is much higher in MSMs (54). A 
previous MACS investigation demonstrated that 85% of all MACS subjects have been infected 
with GBV-C (7). GBV-C transmission occurs via parenteral, sexual, and vertical routes, and 
because of shared transmission modes with HIV-1, HIV-1-positive individuals are often coinfected 
with GBV-C. Although immune-competent hosts typically clear GBV-C viremia, infection can 
persist for years in immune-compromised individuals. Over the last 15 years, several studies have 
demonstrated an association between GBV-C infection, and increased survival, and better health 
outcomes including increased CD4+ count in HIV-positive individuals (6, 55, 56).  
1.3.1 GBV-C in HIV-1 Positive Individuals 
Questions remain regarding the mechanism of the protective effect that GBV-C seems to have 
against HIV-1 infection, and the potential interactions between GBV-C and HIV-1. Recent studies 
have suggested that the GBV-C envelope E2 protein inhibits TCR activation-induced IL-2 release, 
and is associated with high levels of double-negative T cells that limit immune activation (57, 58).  
Additionally, GBV-C has been associated with reduced NK cell and monocyte activation, and may 
be associated with reduced B cell activation (7). This reduction in immune activation can have an 
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impact on the clinical complications associated with the chronic immune activation and 
inflammation that accompany HIV-1 disease progression. 
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2.0  METHODS 
The MACS is a prospective cohort study designed specifically to examine HIV-1 infection in 
MSMs. The MACS is the largest study of its kind, and has recruited nearly 7,000 participants since 
its creation in 1984. Men have been recruited at four sites: Johns Hopkins University in Baltimore, 
Northwestern University in Chicago, the University of California Los Angeles, and the University 
of Pittsburgh. Thus far, the MACS has resulted in over 1,300 publications, and has contributed 
greatly to current knowledge of the epidemiology and the natural history of HIV and AIDS. 
This study specifically examines the role of various viral coinfections in the development 
of NHL in MACS seroconverters pre-cART. The University of Pittsburgh MACS site conducted 
testing for CMV, EBV, HHV-6, and HHV-8 DNA and GBV-C RNA in the blood plasma of 536 
MACS seroconverters pre-cART collected from over 5,000 person-visits. Within this group of 536 
seroconverters, 26 cases of pre-cART NHL within the group were identified to be included within 
this analysis.  
2.1 LABORATORY METHODS 
Nucleic acid was extracted from human plasma specimens utilizing a NucliSENS easyMAG 
automated extractor (bioMerieux Inc., Durham, NC). Known amounts of phocine herpesvirus-1 
(PhHV) an animal herpesvirus and equine arteritis virus (EAV) a single stranded RNA virus were 
added to all samples prior to nucleic acid extraction in order to confirm extraction efficiency, and 
to detect the presence of PCR inhibitors. Five microliter aliquots of the extracts were tested for the 
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presence of CMV, EBV, HHV-6, and HHV-8 viral DNA by real-time PCR conducted in Dr. 
Charles Rinaldo’s University of Pittsburgh Clinical Virology Research Laboratory by Arlene 
Bullotta. The presence of GBV-C RNA was detected utilizing real-time reverse transcriptase PCR 
assay at the University of Pittsburgh Graduate School of Public Health under the direction of Dr. 
Yue Chen. Negative controls consisting of nuclease-free water, and positive controls consisting of 
known amounts of viral nucleic acid were included in each real-time PCR assay. The limits of 
detection and quantitation of viral DNA and RNA were extrapolated using known quantities of 
viral DNA and RNA from Advanced Biotechnologies (ABI, Columbia, MD). The upper and lower 
limits of detection for each of the viral assays are described below in the number of quantities per 
reaction in Table 1. Contamination of the negative control, or failure to detect internal control 
(PhHV or EAV) within a specified Ct value range resulted in the re-extraction of samples and 
repetition of the PCR assay. Primers and probes utilized in the real-time PCR assays are listed 
below in Table 2. 
 
Table 1. Upper and lower limits of detection in number of quantities per reaction 
 CMV EBV HHV-6 HHV-8 GBV-C 
Upper LOD 
(qtx/rx) 500,000 650,000 500,000 400,000 190,000,000 
Lower LOD 
(qtx/rx) 1 2.5 2 1.5 1,900 
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Table 2. Primers and probes utilized for real-time PCR assay 
Target Forward Primer Reverse Primer Probe Reference 
CMV CGATCAAGAACGCGA
TAACG 
ACCGTCGATGGCAGGTCAT 6FAM-CGATCACAAACAGCG-
MGBNFQ 
Snghavi, et al., 
2008 
EBV AAACCTCAGGACCTA
CGCTGC 
AGACACCGTCCTCACCAC 6FAM-
TAGAGGTTTTGCTAGGGAGGAGA
CGTGTG-TAMRA 
Jebbink et al., 
2003 
GBV-C CCAACCCTGTCATCA
CCCATCCACC 
GRTGACCGGGATTTACGACC
T 
Cy5-GCGACCGGCCAAAAGG-BHQ Li et al. 2006 
HHV6 CGCTAGGTTGAGGAT
GATCG 
CAAAGCCAAATTATCAGACG 6FAM-
CACCAGACGTCACACCCGAAGGA
AT-TAMRA 
Locatelli et al., 
2000 
HHV8 GTCTCTTGGACAAGC
TCGCTG 
AGTGAGCATGGCAGATGTTC
GT 
6FAM-
CGGTCTGTGAAACGGTCATTGAC
CTTAC 
Jenkens, 
personal 
communication 
PHHV GGGCGAATCACAGCT
TGAAT 
GCGGTTCCAAACGTACCAA VIC-TTTTATGTGTCCGCCACCAT-
MGB-NFQ 
Neisters et al., 
2002 
EAV GGCGACAGCCTACAA
GCTACA 
CGGCATCTGCAGTGAGTGA 6FAM-TTGCGGACCCGCATCTGACCAA-MGBNFQ 
 
2.2 STATISTICAL ANALYSIS 
A total of 26 HIV-1 MACS seroconverters with NHL pre-cART were identified by the Center 
for Analysis and Management of MACS Data (CAMACS) to have specimens included in viral 
testing conducted at the University of Pittsburgh by Dr. Rinaldo’s and Dr. Chen’s laboratories. 
Four of the seroconverters had only completed one visit, and DNA testing had not been fully 
completed for these individuals so they were excluded from the sample. Thus, 22 HIV-1 MACS 
seroconverters with NHL were included in the sample. Additionally, 514 MACS seroconverters 
who did not develop NHL pre-cART were included in the analysis. Data were described and 
analyzed using STATA/SE 13.0 software (StataCorp College Station, TX).  
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 Fisher’s exact tests were used to measure non-random association of categorical variables 
between the seroconverters who developed NHL and those who did not. The categorical 
variables included race, tobacco use, presence of viremia at least once, and the proportion of 
person-visits from which viremia was detected. The proportion of person-visits from which 
CMV, EBV, HHV-6, HHV-8, or GBV-C viremia was detected was determined by the proportion 
of visits from which viremia for each coinfection was detected among HIV-1 seroconverters who 
developed NHL and those who did not develop NHL. Two-sample t-tests of unequal variance 
were used to compare means of continuous variable (age at HIV-1 seroconversion, and HIV 
RNA set point) between the seroconverters who developed NHL and those who did not develop 
NHL.  
A Mann-Whitney U test was used to compare the quantities of CMV, EBV, HHV-8, and 
GBV-C viremia between the HIV-1 seroconverters who developed NHL and those who did not. 
HHV-6 was not included in this portion of the analysis, because none of the HIV-1 experienced 
HHV-6 viremia detected from the blood plasma. Finally, the 22 seroconverters who developed 
NHL pre-cART were divided into groups based on which viral DNA or RNA had been detected 
in their blood plasma at least once over the course of the study. Two-sample t-tests of unequal 
variance were used to compare the mean length of time from HIV-1 seroconversion to NHL 
diagnosis between HIV-1 seroconverters with various coinfection profiles.  
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3.0  RESULTS 
In total, the study sample included 536 HIV-1 seroconverters pre-cART, including the 22-
participant subsample that developed NHL pre-cART. Characteristics of the 22 seroconverters 
who developed NHL pre-cART, and the 514 seroconverters who did not develop NHL can be 
found in Table 3. The mean age at seroconversion was 35 for all participants, and the average years 
of seroconversion for seroconverters who developed NHL and those who did not develop NHL 
were 1988 and 1989, respectively. In both groups, the majority of participants were white non-
Hispanic individuals; however, there were significantly more black and Hispanic men in the group 
of seroconverters who did not develop NHL (P = 0.036). The proportions of current and former 
smokers (36% and 49%) were significantly higher in the group of seroconverters who developed 
NHL compared to that measure within the group that did not develop NHL (30% and 40%). Table 
3 also describes the proportion of individuals from each group whose plasma had detectable 
quantities of CMV, EBV, HHV-6, and HHV-8 DNA or GBV-C RNA at least once. The 
proportions of seroconverters who had detectable CMV, and EBV viremia at least once were 
slightly higher in those who developed NHL (CMV 59.09% vs. 50.23%, EBV 81.82% vs. 
67.91%), and the proportion who had detectable HHV-8 and GBV-C viremia at least once was 
higher in those who did not develop NHL (HHV-8 33.18% vs. 18.18%, GBV-C 47.45% vs. 
36.36%). HHV-6 DNA was not detected in the blood plasma of the seroconverters who developed 
NHL, and very few individuals from either group never experienced detectable viremia for any of 
the herpesvirus or GBV-C coinfections (4.76% and 2.09%). None of these differences between the 
two groups were statistically significant. In order to better compare sustained viremia between the 
two groups, the percentage of person-visits from which viral DNA and RNA were detected was 
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compared between the two groups for each virus. Additionally, the percentage of person-visits 
from which no herpesvirus DNA or GBV-C RNA were detected was compared between the 
seroconverters who developed NHL, and those who did not develop NHL. The group of 
seroconverters who developed NHL had a significantly higher of percentage of person-visits from 
which CMV, and EBV DNA were detected (P < 0.001 for each). Contrarily, the group who did 
not develop NHL had a significantly higher percentage of person-visits from which either no 
viremia was detected, or from which GBV-C RNA was detected (P = 0.000 and 0.018 
respectively). Lastly, the HIV-1 RNA set point was found to be higher in the individuals who 
developed NHL, but this difference was not significant until the measurement was converted to 
log10 form. 
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 Table 3. Characteristics of the study sample 
   HIV-1 Seroconverters Who Developed NHL 
HIV-1 Seroconverters 
Who Did Not Develop 
NHL 
P-value 
*Fisher’s exact 
or t-test 
Total Number of Individuals 22 514 536 
Avg. Year of Seroconversion 1988 1989 NA 
Avg. Year of NHL Diagnosis 1996 NA NA 
Mean Age at Seroconversion 35.56 35.6 0.982 
Race 
Black 5% (1) 7% (37) 
0.036 White 95% (21) 92% (472) 
Other 0 1% (5) 
Smoke Tobacco 
Never Smoked 15% 30% 
0.000 Former Smoker 49% 40% 
Current Smoker 36% 30% 
CMV viremia detected at least once 59.09% 50.23% 0.514 
EBV viremia detected at least once 81.82% 67.91% 0.239 
HHV-6 viremia detected at least once 0.00% 3.94% 1.000 
HHV-8 viremia detected at least once 18.18% 33.18% 0.167 
GBV-C viremia detected at least once 36.36% 47.55% 0.384 
Viremia never detected 4.76% 2.09% 0.395 
Person-visits where CMV viremia detected 25.84% 12.24% 0.000 
Person-visits where EBV viremia detected 43.89% 26.24% 0.000 
Person-visits where HHV-6 viremia detected 0 0.58% 1.000 
Person-visits where HHV-8 viremia detected 7.87% 9.04% 0.688 
Person-visits where GBVC viremia detected 28.89% 37.72% 0.018 
Person-visits where no viremia detected 20.25% 37.95% 0.000 
HIV RNA Set Point 90,594 copies per ml 58,481 copies per ml 0.410 
HIV RNA Set Point log 10 4.66 4.24 0.026 
 
 
 Next, within those whose plasma contained detectable levels of herpesvirus DNA or GBV-
C RNA the quantities of viral DNA and RNA were compared between the two groups using a two-
sample Mann-Whitney U test. Differences in the quantities CMV and HHV-8 DNA were not found 
to be significant by the Mann-Whitney test. The median quantity of EBV DNA was significantly 
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higher in the HIV-1 seroconverters who developed NHL (207.5 vs. 121 copies per ml; P < 0.0001). 
Contrarily, the quantity of GBV-C RNA per ml of plasma was found to be significantly higher in 
those who did not develop NHL (P = 0.0002) using the Mann-Whitney U test. These results are 
described in Table 4.  
Table 4. Comparison of viral quantities between HIV-1 seroconverters who did and did not develop NHL 
  Percentiles  
Virus & Group Mean Viral Copies per ml 25th 50th (median) 75th 
P-Value 
*Mann-Whitney U 
CMV     0.866 
NHL 896.52 104 360 882  
No NHL 668.21 74.5 374 909.5  
EBV     0.0000 
NHL 931.32 114 207.5 499  
No NHL 82.47 60 121 242  
HHV-8     0.111 
NHL 554.35 51 338 1227  
No NHL 1233.51 149 1188 3273  
GBV-C     0.0002 
NHL 2.33E+08 8.90E+06 7.89E+07 4.51E+08  
No NHL 1.10E+09 6.23E+07 4.04E+08 1.05+09   
 
 
The various combinations of viral coinfections within the group of seroconverters who 
developed NHL pre-cART were determined based on the presence of viral DNA or RNA having 
been detected in the participant’s blood plasma at least once. The most frequently observed 
coinfection profile was concurrent CMV and EBV (six individuals), and the least common 
coinfection profiles were GBV-C coinfection alone, and concurrent CMV and GBV-C 
coinfections (one individual each). Only one seroconverter who developed NHL pre-cART had no 
detectable herpesvirus DNA or GBV-C RNA in blood plasma obtained from at least one person-
visit. The average time from HIV-1 seroconversion to NHL diagnosis was calculated for each 
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participant who developed NHL. The overall average number of years from HIV-1 seroconversion 
to the development of NHL was 7.47 years.  
The average number of years from HIV-1 seroconversion to NHL diagnosis was then 
compared based on detection of CMV, EBV, HHV-8, and GBV-C at least once in order to 
determine any potential effects of viremia on NHL development. The time to NHL diagnosis was 
also compared based on the various combinations of coinfections observed within the study 
population. Unfortunately, due to the small sample size and insufficient frequency of select 
coinfection profiles, select profiles could not be included in the comparison. Lastly, because it 
was hypothesized that the presence of herpesvirus DNA and the presence of GBV-C RNA have 
the opposite effect HIV-1 disease progression and the development of NHL, the average time to 
NHL diagnosis was examined for each of the herpesviruses without GBV-C and vice versa. All 
data regarding the differences in mean time to NHL diagnosis can be found in Table 5.  
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Table 5. Average number of years from HIV-1 seroconversion to NHL diagnosis by coinfection 
 Average Years from Seroconversion to NHL Diagnosis (n)  
Any Presence Of: Viremia Detected  Viremia Not Detected p-value *Fisher’s exact 
CMV 7.38 (13) 7.63 (9) 0.782 
EBV 7.05 (18) 10 (4) 0.007 
HHV-8 6 (4) 7.82 (18) 0.077 
GBVC 8.13 (8) 7.08 (14) 0.218 
Viruses with Competing Effects: Combination Present Combination Absent  
CMV + GBV-C - 7.53 (8) 7.53 (14) 0.824 
EBV + GBV-C - 6.92 (12) 8.22 (10) 0.113 
HHV-8 + GBV-C - 6.33 (4) 7.67 (18) 0.267 
GBV-C + CMV - 7 (3) 7.53 (19) 0.694 
GBV-C + EBV - 10.5 (3)  7.16 (19) 0.0219 
GBV-C + HHV-8 - 8.29 (8) 7.07 (14) 0.171 
Unique Combinations: Combination Present Combination Absent  
EBV + GBV-C + 7.5 (2) 7.47 (20) 0.98 
CMV + EBV + 6.82 (6) 8.2 (16) 0.089 
EBV + HHV-8 + 6 (2) 7.82 (20) 0.038 
CMV + EBV+ GBV-C + 7.5 (4) 7.47 (18) 0.967 
CMV + EBV + HHV-8 + 5.5 (2) 7.68 (20) 0.048 
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4.0  DISCUSSION 
There were several differences observed between the MACS HIV-1 seroconverters who developed 
NHL pre-cART and the MACS HIV-1 seroconverters who did not develop NHL. First, there was 
a significantly higher percentage of white males in the group of seroconverters who developed 
NHL compared to those who did not. This observation is in agreement with body of evidence 
suggesting that in the United States white individuals are at an increased risk of NHL. Additionally, 
smoking (former or current) was significantly associated with the development of NHL in MACS 
HIV-1 seroconverters.  This observation is interesting, because whether smoking is a risk factor 
associated with the development of NHL has been frequently debated in literature. HIV RNA viral 
set point was also significantly higher in those who developed NHL. This association is in 
agreement with existing evidence that demonstrates the effects that HIV-1 RNA set point may 
have on HIV-1 disease progression over time. 
Although the percentage of seroconverters with detectable herpesvirus or GBV-C viremia 
at least once differed slightly between those who developed NHL and those who did not, none of 
these differences were significant. However, the HIV-1 seroconverters who developed NHL 
exhibited CMV, and EBV viremia significantly more frequently than those who did not develop 
NHL. Contrarily, those who did not develop NHL experienced GBV-C viremia significantly more 
frequently than the seroconverters who did develop NHL. Furthermore, the seroconverters who 
did not develop NHL were significantly more likely to have no detectable herpesvirus or GBV-C 
viremia during annual person-visits. These observations are in agreement with the hypothesis that 
CMV, and EBV coinfections may contribute to NHL development in HIV-1 positive individuals, 
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and that GBV-C coinfection has a protective effect against the development of NHL in HIV-1 
positive individuals.  
Only 3.94% of the study sample ever experienced HHV-6 viremia that was detectable by 
DNA in the blood plasma, and none of these HHV6-positive individuals developed NHL. The 
association of HHV-6 with the development of various HIV/AIDS-associated cancers including 
NHL remains unclear in literature. This investigation did not find any association between HHV-
6 DNA and NHL development. Additionally, the observations that the prevalence of HHV-8 
viremia, and the frequency of HHV-8 viremia did not differ significantly between the two groups 
are interesting. Research has suggested that HHV-8 infection is associated with the development 
of certain types of NHL in HIV-1 positive individuals, and HHV-8 viral DNA has been detected 
NHL tumors by numerous investigators. However, there was not a significant association between 
HHV8 viremia and the development of NHL observed in this study. Instead, there were slightly 
fewer seroconverters who had ever experienced HHV-8 viremia detectable from blood plasma 
among those who developed NHL. This finding is in agreement with that of another MACS 
investigation that found no associated between serum levels of HHV-8 DNA and NHL 
development in HIV-1 positive individuals. In order to better understand the role of HHV-8 
infection in NHL development it may be helpful, and necessary, to expand this investigation to 
other body compartments that may be infected by HHV-8. It was found that seroconverters with 
detectable EBV and HHV-8 coinfection, and seroconverters with detectable CMV, EBV, and 
HHV-8 coinfection progressed to NHL significantly more quickly than the seroconverters with 
other detected coinfection profiles.  
When comparing the average number of viral copies of each of the herpesviruses and GBV-
C detected in the blood plasma of the seroconverters who developed NHL and those who did not, 
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only the quantities of EBV and GBV-C differed significantly between the two groups (p-value: 
0.00). Higher quantities of EBV DNA were detected in those who developed NHL and higher 
quantities of GBV-C RNA were detected in those who did not develop NHL. Again, this finding 
is in agreement with the hypothesis that EBV contributes to the development of NHL in HIV-1 
seroconverters, and that GBV-C helps reduce immune activation associated with HIV-1 infection, 
and has a protective effect against the development of negative health outcomes associated with 
HIV-1 disease progression. Higher mean quantities of CMV DNA were detected in the 
seroconverters who developed NHL; however these differences were not significant. Because none 
of the seroconverters in the NHL group had detectable HHV-6 viremia, the average quantities of 
HHV-6 DNA could not be compared between the two groups. 
The seroconverters who developed NHL pre-cART were categorized based on the various 
coinfections that had been detected in each of their blood plasma. Next the average number of 
years from HIV-1 seroconversion to NHL diagnoses was determined for each coinfection profile. 
Seroconverters who progressed to NHL most slowly were those with no detectable coinfections (9 
years), only detectable GBV-C coinfection (10 years), or CMV and GBV-C coinfection (11 years). 
Since these scenarios each only occurred in one individual, the average time to NHL diagnosis 
could not be determined, and therefore, could not be compared to the other groups utilizing a mean 
comparison test. The average time to NHL diagnosis was instead only compared between 
coinfection profiles with a sufficient number of seroconverters to determine an average. Two 
coinfection combinations were associated with significantly less time between HIV-1 
seroconversion and NHL diagnosis: EBV and HHV-8 coinfection (6 years average, P = 0.038), 
and CMV, EBV and HHV-8 coinfection (5.5 years average, P = 0.048). This finding suggests 
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these combinations of herpesvirus coinfections are associated with more rapid development of 
NHL in HIV-1 positive individuals.  
Additionally, the mean time from seroconversion to NHL diagnosis was compared between 
individuals who had ever experienced detectable viremia, and those who had never experienced 
detectable viremia for each of the viral coinfections. Seroconverters who had ever experienced 
detectable CMV, or HHV-8 viremia developed NHL more rapidly than those who had never 
experienced detectable viremia for those viruses; however this difference was not significant. 
Similarly, those who had been viremic for GBV-C at least once had a greater average length of 
time between seroconversion and NHL diagnosis, but the difference was not significant. However, 
GBV-C positive individuals who did not have detectable EBV viremia had the greatest average 
time length from HIV-1 seroconversion to NHL diagnosis (10.5 years P = 0.022), suggesting that 
GBV-C coinfection is associated with slower development of NHL in HIV-1 positive individuals. 
Contrarily, seroconverters who had ever experienced detectable EBV viremia were diagnosed with 
NHL an average of three years sooner than those who never had detectable EBV viremia (7.05 
years vs. 10 years, P = .007), suggesting that the presence of EBV DNA in blood plasma is 
associated with more rapid development of NHL in HIV-1 positive individuals. Both of these 
findings support the hypothesis that the chronic immune activation and inflammation associated 
with herpesvirus infection may contribute to the development of NHL in HIV-1 positive 
individuals, and that GBV-C coinfection may have a protective effect against the development of 
NHL in HIV-1 positive individuals.  
 30 
4.1 LIMITATIONS & FUTURE DIRECTIONS 
The greatest limitation of this investigation was the small sample size of the HIV-1 seroconverters 
who developed NHL pre-cART. Because some occurrences, such as lack of detectable 
coinfections, were so rare within the sample the options for statistical analysis were quite limited. 
In the future, it would be valuable to expand this investigation to a larger study sample. Including 
HIV-1 seroprevalent individuals, and individuals who were diagnosed with NHL post-cART 
would allow for a more robust statistical analysis.  
 Additionally, in order to fully determine the effects of CMV, EBV, HHV-6, HHV-8 and 
GBV-C coinfection on chronic immune activation and inflammation in HIV-1 positive individuals, 
biomarkers of immune activation and inflammations should be included in the analysis. 
Comparing levels of biomarkers of immune activation and inflammation with the presence of viral 
coinfections in HIV-1 positive individuals would illuminate many unanswered questions regarding 
the dynamics of viral coinfections in HIV-1 disease progression and their role in the development 
in inflammatory diseases. In addition to including immune biomarkers in future analysis, it would 
be valuable to expand viral DNA and RNA detection to other body compartments in addition to 
blood plasma. This study suggests that although detectable HHV-8 DNA in blood plasma is not 
associated with the development of NHL, among those who develop NHL, detectable HHV-8 
DNA in the blood plasma is associated with more rapid development of NHL following 
seroconversion. Testing for HHV-8 DNA in blood cells that it targets, e.g. B cells, monocytes, 
dendritic cells, and additional body compartments may better clarify the true role of HHV-8 
infection in the development of NHL.  
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5.0  PUBLIC HEALTH SIGNIFICANCE 
NHL is the seventh most common cancer in the U.S. and is estimated to be the tenth most common 
cancer in the world, resulting in over 350,000 new cases each year (59). It affects individuals of 
all ethnicities and socioeconomic status, and the global incidence of NHL has continued to increase 
in recent years (59). Better understanding the risks associated with the development of NHL can 
contribute to the early detection and prevention of cases. Although this study focused on NHL in 
HIV-1 positive individuals, knowledge gained regarding the association of chronic immune 
activation due to infection on the development of NHL can be applied to the general population. 
This is particularly true for immune activation due to herpesvirus coinfections, because they are 
so widespread among the general population. 
  HIV-1 infection is the most important factor contributing to one’s likelihood of developing 
NHL, and it is estimated that 5-25% of all HIV-1-positive individuals will develop NHL. Although 
the introduction of cART has reduced the incidence of NHL tremendously, other risk factors for 
NHL in HIV-1-positive individuals include age, and length of time from seroconversion. It is likely 
that as a greater number of HIV-1-positive individuals receive treatment, and live longer lives, the 
burden global burden of NHL will continue to increase. In the U.S. NHL is typically treated with 
chemotherapy, radiation, or immunotherapy, and the average five-year survival rate is over 70% 
(59). However, the mean survival times differ greatly among the various subtypes of NHL, and 
the means survival times are much lower in those with HIV. In some areas of the world, 
particularly those where the HIV-1 burden is highest, these treatment options are not always 
accessible. Moreover, estimates suggests that over 70% of cancer patients are diagnosed at late 
stage of illness in the developing world (21). For these reasons, it is essential that a greater 
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understanding of the risks associated with NHL development in HIV-1-positive individuals are 
better understood in order to detect and prevent cases in populations with high HIV prevalence. 
Additionally, programs aimed at increasing the accessibility of HIV-1 treatment globally should 
consider incorporating efforts to help build the capacity of health care systems so that they not 
only address the burden of HIV-1, but also the increasing burden of HIV-1-associated 
malignancies such as NHL. 
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